TP53 and osteosarcoma: We reviewed previous studies on prognostic-related molecular markers and found that the vascular endothelial growth factor (VEGF) and p53 mutation were two important biomarkers related to the evaluation of the biological aggressiveness of osteosarcoma and GCTB (3, 8–15).